Fenel Eloi is a seasoned executive in the life sciences sector. He is currently the Managing Partner of P&M Capital Partners, LLC, a private equity firm engaged in angel investing of life sciences startups. He was the Chief Operating Officer and Chief Financial Officer of Cell Signaling Technology, Inc., a privately held life sciences company, from September 2005 to March 2018. Prior to that, he was the Chief Operating Officer of Interleukin Genetics, Inc., a formerly Nasdaq-listed diagnostics company, for five years. Prior to Interleukin, he was Chief Financial Officer at LifeCell Corp. and Genome Therapeutics Corp., both formerly Nasdaq-listed companies, for a combined period of 12 years. Fenel currently serves on the Board of 908 Devices Inc., a Nasdaq-listed company. He also serves on the boards of Vaxess Technologies Inc., Ultivue, Inc., and Mitotherapeutix, LLC, all private life sciences companies. He also serves on the board of VIC Technology Venture Development, a life sciences venture investment company. During his professional career, Fenel has scaled up operations, expanded businesses both organically and through strategic partnerships and completed a number of public and private financing transactions. His leadership experience ranges from startup companies to multinationals. Fenel has an MBA from Anna Maria College and a BA in Business and Finance from Lee University.